Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Dual-Mode ...

    2026-01-13

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Dual-Mode Reporter for Mammalian Expression

    Executive Summary: EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is a chemically modified, Cap1-capped mRNA reporter optimized for mammalian systems (APExBIO product page). It encodes Photinus pyralis luciferase, supporting ATP-dependent bioluminescence at 560 nm and incorporates Cy5 for direct fluorescence tracking (excitation/emission: 650/670 nm). The product's 5-methoxyuridine modification and Cap1 structure enhance translation efficiency and suppress innate immune activation, as shown in recent in vivo studies (Shao et al. 2025). It is delivered at ~1 mg/mL in 1 mM sodium citrate (pH 6.4), shipped on dry ice, and intended for rigorous mRNA delivery, translation, and imaging applications.

    Biological Rationale

    mRNA-based reporter systems are essential for quantifying gene delivery, translation efficiency, and cellular viability in mammalian systems. Firefly luciferase provides chemiluminescent output upon oxidation of D-luciferin in the presence of ATP, enabling sensitive, quantitative detection of gene expression (Shao et al. 2025). Fluorescent labeling, such as Cy5, allows for real-time visualization of mRNA uptake and intracellular trafficking. Chemical modifications like 5-methoxyuridine triphosphate (5-moUTP) are known to reduce innate immune stimulation and increase transcript stability, overcoming barriers to in vivo mRNA applications (Advancing In Vivo mRNA Imaging). Cap1 structures, unlike Cap0, further decrease recognition by innate immune sensors (e.g., IFIT proteins), promoting efficient translation in mammalian cells.

    Mechanism of Action of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)

    • Cap1 Structure: The mRNA features a Cap1 structure enzymatically added post-transcription via Vaccinia Virus Capping Enzyme (VCE), GTP, S-adenosylmethionine (SAM), and 2'-O-Methyltransferase. This modification increases translation efficiency and reduces immunogenicity in mammalian cells (Shao et al. 2025).
    • 5-methoxyuridine (5-moUTP) Incorporation: 5-moUTP replaces uridine in a significant fraction of the transcript, decreasing recognition by innate immune receptors (e.g., TLR3, TLR7/8) and enhancing mRNA stability and translation (Advancing In Vivo mRNA Imaging).
    • Cy5-UTP Labeling: Cy5, a red fluorescent dye (Ex/Em 650/670 nm), is incorporated at a 3:1 ratio with 5-moUTP. This permits direct tracking of mRNA in cells and tissues without impairing translation (Innovations in Reporter Assays).
    • Poly(A) Tail: The mRNA contains a polyadenylated tail to enhance stability and translation initiation.
    • Storage and Handling: Provided at ~1 mg/mL in 1 mM sodium citrate (pH 6.4), the product requires storage at -40°C or below, handling on ice, and protection from RNases.

    Evidence & Benchmarks

    • Cap1-capped, chemically modified mRNAs demonstrate significantly higher translation efficiency compared to Cap0 mRNAs in mammalian cell lines (Shao et al. 2025, DOI).
    • 5-moUTP incorporation reduces activation of TLR7/8 and type I interferon response in human and murine immune cells (Shao et al. 2025, DOI).
    • Cy5 labeling does not impair luciferase translation or enzymatic activity, as shown in dual-mode reporter assays (Innovations in Reporter Assays, internal link).
    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) enables robust in vivo imaging and ex vivo quantification of mRNA delivery in mouse models (Advancing In Vivo mRNA Imaging, internal link).
    • Poly(A) tailing is essential for transcript stability and efficient translation initiation in eukaryotic cells (Shao et al. 2025, DOI).

    Applications, Limits & Misconceptions

    • Designed for high-sensitivity mRNA delivery and transfection studies in mammalian cells (Innovations in Dual-Mode Detection). This article clarifies the distinct role of Cap1 and 5-moUTP in immune evasion, extending the focus beyond dual detection.
    • Supports translation efficiency assays, cell viability studies, and quantitative in vivo bioluminescence imaging.
    • Cy5 fluorescence enables real-time tracking of mRNA uptake and biodistribution.
    • Not intended for therapeutic or clinical applications; for research use only.

    Common Pitfalls or Misconceptions

    • Pitfall: Assuming Cy5 labeling completely replaces the need for bioluminescent quantification.
      Clarification: Cy5 enables tracking, not quantification of translation or enzymatic activity.
    • Pitfall: Using the reagent at temperatures above -40°C for extended periods.
      Clarification: Storage above -40°C or repeated freeze-thaw cycles may degrade mRNA.
    • Pitfall: Omission of RNase-free technique.
      Clarification: RNase contamination will rapidly degrade mRNA and compromise results.
    • Pitfall: Expecting applicability for human therapy.
      Clarification: The product is for research applications only; not approved for clinical use.
    • Pitfall: Treating Cap1 and 5-moUTP modifications as interchangeable.
      Clarification: Cap1 primarily improves translation and immune evasion, while 5-moUTP suppresses innate immune activation via TLR7/8.

    Workflow Integration & Parameters

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is delivered at ~1 mg/mL in 1 mM sodium citrate, pH 6.4. Use sterile, RNase-free materials and handle samples on ice. For transfection, standard lipid-based or nanoparticle reagents are compatible. Typical in vitro transfection protocols employ 100–500 ng mRNA per well (24-well format). For in vivo studies, adjust dosing per animal weight and tissue target (EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)).

    Readout can be achieved via: (1) Bioluminescence using D-luciferin substrate (peak emission ~560 nm); (2) Cy5 fluorescence microscopy (Ex/Em 650/670 nm). The dual-mode capability supports direct correlation between delivery (fluorescence) and functional translation (bioluminescence) (EZ Cap Cy5 Dual-Mode Reporter). This article provides detailed workflow parameters and benchmark data not covered in prior overviews.

    Conclusion & Outlook

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), manufactured by APExBIO, provides a rigorously validated, dual-mode reporter for mRNA delivery and expression studies. Its advanced Cap1 capping, 5-moUTP modification, and Cy5 labeling enable high translation efficiency, immune evasion, and multimodal detection. The reagent is an essential tool for quantitative mRNA research and next-generation in vivo imaging, supporting continuous innovation in translational studies (Pushing the Frontiers of Translational Research). This article updates previous content by integrating new data on workflow robustness and practical pitfalls for reliable mammalian use.